Payer-Reported Unmet Need Burden and Expectations From Future Treatments in Breast Cancer

Author(s)

Peeyush Potdar, B.PHARM, MBA.
Delivery Head, eQuantX Pharma Analytics Solutions, Gurugram, India.
OBJECTIVES: Despite progress in the treatment of advanced/metastatic breast cancer, treatment is palliative and ineffective in some patient subpopulations. This research elucidates the areas of unmet need in managing breast cancers and the expected characteristics from future treatments.
METHODS: Ten private and institutional payers in the United States were interviewed in 2024.
RESULTS: Most payers emphasized the need for novel biomarkers for a personalized treatment approach to improve treatment outcomes and minimize cost burden. Triple-negative breast cancer (TNBC) is not as effectively treated as other subtypes of breast cancer because at least one-third of TNBC patients do not experience a complete response to current treatments. Because of the aggressive nature of this type of disease, the majority of patients die within a few years. For HER2-positive breast cancer patients, current treatments do not adequately address rapidly progressing brain metastases. For these metastases, drug development is challenging because of the blood-brain barrier, which prevents drugs from exerting antitumor activity in the brain. Elderly patients with breast cancer are typically undertreated, and the number of elderly patients with breast cancer is increasing. Elderly patients are often excluded from clinical trials, so data on the efficacy of novel treatments in these patients is often lacking. For HER2+ breast cancer patients, recurrence of the disease state is particularly challenging. An unmet need exists in developing agents that can give patients longer, more durable responses or can be efficacious when a patient stops responding to trastuzumab or other HER2-targeted therapies.
CONCLUSIONS: This research provides directional insights to drug developers on the needs of breast cancer patients and payer expectations from future treatments in this indication.

Conference/Value in Health Info

2025-09, ISPOR Real-World Evidence Summit 2025, Tokyo, Japan

Value in Health Regional, Volume 49S (September 2025)

Code

RWD47

Topic Subcategory

Distributed Data & Research Networks

Disease

SDC: Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×